Morocco,South Africa,Australia,China,Hong Kong SAR China,Japan,Korea,New Zealand,Singapore,Thailand,Austria,Belgium,Czech Republic,Denmark,Finland,France,Germany,Hungary,Ireland,Italy,Luxembourg,Netherlands,Norway,Poland,Portugal,Romania,Slovak Republic,Spain,Sweden,United Kingdom,Argentina,Chile,Mexico,Peru,Bahrain,Oman,Qatar,UAE,Canada,Puerto Rico,United States
Strategic transactions in the life sciences industry fuel transformation and innovation. We’re trusted advisors to many of the world’s leading life sciences companies, and we work on more mergers and acquisitions than any other law firm. No matter how complex, we’ll help you maximize business expansion opportunities.
Whether your business is an emerging growth company looking to fund growth and expansion, or an established multinational investing in an acquisition to enhance R&D pipelines, we can provide guidance at every step.
We help clients with thousands of strategic transactions every year, negotiating advantageous terms, designing and implementing creative structures, and tactically executing deals.
Across the life sciences industry, we advise on the full spectrum of transactions that help clients achieve business goals – corporate finance transactions, mergers and acquisitions, strategic partnerships, outsourcing and manufacturing agreements, licensing, R&D, and digital transformation initiatives.
“Our advice is seamless, integrated, and incorporates deep local knowledge.”
We’re recognized in particular for our M&A work. Over the 16 years we have been ranked top of the Mergermarket tables, we have advised on over 12,800 deals for a total disclosed value of more than USD2 trillion. That’s more deals than any other law firm.
Our advice is comprehensive, covering all aspects of deals – from licensing IP rights and executing manufacturing agreements to accessing global funding sources and complying with global regulations.
We have offices in 40+ countries, and our lawyers collaborate closely across our broad range of practice groups including Tax, Employment, IP, and Regulatory and Government Affairs. This means our advice is seamless, integrated, and incorporates deep local knowledge. We flag potential hurdles in each country, advise on regulatory nuances, and manage the most demanding due diligence exercises to ensure the success of cross-border transactions.
Ranked as the number 1 most active law firm for combined global deal volume in venture capital, private equity and M&A, and recognized as one of the most active legal advisors in the following venture capital sectors: biotech, healthcare devices, healthcare services, commercial services, energy, consumer goods, IT, pharma, media, and software, PitchBook 2022
Experience
Our experience includes advising:
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, on its US$3.9 billion acquisition by Merck KGaA, a leading global science and technology company.
Mallinckrodt plc, a global specialty pharmaceutical company, on its US$6.7 billion combination with Endo, Inc., resulting in Endo becoming a wholly owned subsidiary of Mallinckrodt.
Kadmon Holdings, Inc. (NASDAQ: KDMN), a biopharmaceutical company that discovers, develops, and markets transformative therapies for unmet medical needs, on its US$1.9 billion acquisition by Sanofi S.A., a global biopharmaceutical company.
A biotechnology company, on its US$1.8 billion sale to Roche, one of the world's largest biotechnology companies.
Channel Biosciences, Inc., a biotechnology company focused on therapeutic development, on the US$1.24 billion sale of its subsidiary Channel Biosciences to Biohaven Ltd., a biopharmaceutical company focused on innovative therapies for neurological and neuropsychiatric diseases.
A life sciences company, on its US$1.1 billion sale to Asahi Kasei Corporation, a diversified multinational company active in healthcare and life sciences.
Alfasigma S.p.A., a global pharmaceutical company focused on specialty therapeutics, on its US$690 million global licensing agreement with GSK granting exclusive worldwide rights to linerixibat, a next-generation therapy for rare cholestatic liver diseases.
TG Therapeutics, Inc. (Nasdaq: TGTX), a biopharmaceutical company focused on B-cell diseases, on the US$650 million sale of European rights to BRIUMVI® (ublituximab), an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis.
Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of therapeutics for progressive non-viral liver diseases, on its transaction to sublicense to Advanz Pharma the rights to commercialize Ocaliva® outside the United States and sell certain foreign subsidiaries and rights regarding its international operations in a transaction valued at up to US$450 million.
Mesa Biotech, Inc., a molecular diagnostics company focused on point-of-care testing solutions, on its US$550 million acquisition by Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science.
